Building on this strategy, Zhang et al., designed a quadrivalent CAR-M system capable of simultaneously targeting FAP (on CAFs) and GPC3 (on tumour cells) while expressing a dominant-negative TGF-β receptor to resist stromal-mediated immunosuppression (102). Here, GPC3 is linked to neoplasm.